ReviewEuropean heart journal2011
Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.
Review in European heart journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 111 citations in OpenAlex.
- Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2017Trial
- Effects of calcium channel blocker-based combinations on intra-individual blood pressure variability: post hoc analysis of the COPE trial.Hypertension research : official journal of the Japanese Society of Hypertension · 2016Trial
- The Effects of Music on Inflammation: A Bibliometric Study from 1989 to 2024.Journal of inflammation research · 2026Review
- Combined RAS Modulation: The Effect on Plasma and Tissue Angiotensin Peptide Levels.Physiological research · 2025Article
- Toll-like receptor 4 mutation mitigates gut microbiota-mediated hypertensive kidney injury.Pharmacological research · 2024Article
- The Retinal Renin-Angiotensin-Aldosterone System: Implications for Glaucoma.Antioxidants (Basel, Switzerland) · 2022Article
- Role of store-operated Ca2+ entry in cardiovascular disease.Cell communication and signaling : CCS · 2022Review
- Effect of renal denervation on long-term outcomes in patients with resistant hypertension.Cardiovascular diabetology · 2021Review
- Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat?Clinical science (London, England : 1979) · 2021Article
- Renin-Angiotensin-Aldosterone System: Friend or Foe-The Matter of Balance. Insight on History, Therapeutic Implications and COVID-19 Interactions.International journal of molecular sciences · 2021Article
- Circulating Renalase as Predictor of Renal and Cardiovascular Outcomes in Pre-Dialysis CKD Patients: A 5-Year Prospective Cohort Study.Life (Basel, Switzerland) · 2021Article
- Influence of Antihypertensive Treatment on RAAS Peptides in Newly Diagnosed Hypertensive Patients.Cells · 2021Article
- Device-Based Sympathetic Nerve Regulation for Cardiovascular Diseases.Frontiers in cardiovascular medicine · 2021Review
- One amino acid change of Angiotensin II diminishes its effects on abdominal aortic aneurysm.Bioscience reports · 2019Article
- Heart Failure in Type 2 Diabetes Mellitus.Circulation research · 2019Review
- Synergistic effect of renalase and chronic kidney disease on endothelin-1 in patients with coronary artery disease ‒ a cross-sectional study.Scientific reports · 2018Article
- A Practical Approach to Hypertension Management in Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2017Review
- Article
- Antihypertensive and Antihypertrophic Effects of Acupuncture at PC6 Acupoints in Spontaneously Hypertensive Rats and the Underlying Mechanisms.Evidence-based complementary and alternative medicine : eCAM · 2017Article
- Hypertension in Patients with Heart Failure with Reduced Ejection Fraction.Current cardiology reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The conventional antihypertensive therapies including renin-angiotensin-aldosterone system antagonists (converting enzyme inhibitors, receptor blockers, renin inhibitors, and mineralocorticoid receptor blockers), diuretics, β-blockers, and calcium channel blockers are variably successful in achieving the challenging target blood pressure values in hypertensive patients. Difficult to treat hypertension is still a commonly observed problem world-wide. A number of drugs are considered to be used as novel therapies for hypertension. Renalase supplementation, vasopeptidase inhibitors, endothelin antagonists, and especially aldosterone antagonists (aldosterone synthase inhibitors and novel selective mineralocorticoid receptor blockers) are considered an option in resistant hypertension. In addition, the aldosterone antagonists as well as (pro)renin receptor blockers or AT(2) receptor agonists might attenuate end-organ damage. This array of medications has now been complemented by a number of new approaches of non-pharmacological strategies including vaccination, genomic interference, controlled breathing, baroreflex activation, and probably most successfully renal denervation techniques. However, the progress on innovative therapies seems to be slow and the problem of resistant hypertension and proper blood pressure control appears to be still persisting. Therefore the regimens of currently available drugs are being fine-tuned, resulting in the establishment of several novel fixed-dose combinations including triple combinations with the aim to facilitate proper blood pressure control. It remains an exciting question which approach will confer the best blood pressure control and risk reduction in this tricky disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.